UMIN-CTR Clinical Trial

BACK TOP
UMIN-CTR English Home Glossary (Simple) FAQ Search clinical trials

Name:
UMIN ID:

Recruitment status No longer recruiting
Unique ID issued by UMIN UMIN000022571
Receipt No. R000026003
Scientific Title Evaluation of Clinicopathological Factors in Patients with Resected Stage I-IIIA Breast Cancer (N-SAS-BC 01/CUBC Biomarker Study)
Date of disclosure of the study information 2016/06/01
Last modified on 2020/06/03

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information
Public title Evaluation of Clinicopathological Factors in Patients with Resected Stage I-IIIA Breast Cancer (N-SAS-BC 01/CUBC Biomarker Study)
Acronym Evaluation of Clinicopathological Factors in Patients with Resected Stage I-IIIA Breast Cancer
Scientific Title Evaluation of Clinicopathological Factors in Patients with Resected Stage I-IIIA Breast Cancer (N-SAS-BC 01/CUBC Biomarker Study)
Scientific Title:Acronym Evaluation of Clinicopathological Factors in Patients with Resected Stage I-IIIA Breast Cancer
Region
Japan

Condition
Condition breast cancer
Classification by specialty
Hematology and clinical oncology Breast surgery
Classification by malignancy Malignancy
Genomic information NO

Objectives
Narrative objectives1 1) To evaluate the efficacy of adjuvant CMF and UFT for each IHC-based intrinsic subtype and the association of the amount of tumor-infiltrating lymphocytes with prognosis and treatment outcome by analyzing the relationship between clinicopathological factors and medical information (prognostic information) in patients with resected stage I-IIIA breast cancer.
2) To re-evaluate the NSAS Grading System, the grading criteria formulated during the NSAS-BC 01 study, by central review of pathological grades.
Basic objectives2 Efficacy
Basic objectives -Others
Trial characteristics_1 Exploratory
Trial characteristics_2 Others
Developmental phase Not applicable

Assessment
Primary outcomes Relapse free survival
Key secondary outcomes Overall survival

Base
Study type Observational

Study design
Basic design
Randomization
Randomization unit
Blinding
Control
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment

Intervention
No. of arms
Purpose of intervention
Type of intervention
Interventions/Control_1
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10

Eligibility
Age-lower limit

Not applicable
Age-upper limit

Not applicable
Gender Female
Key inclusion criteria 1)Subjects were selected from the 1054 patients enrolled and analyzed in the N-SAS-BC 01 and CUBC trials, and were included in the study if the applicable institutional review board authorized the sending of samples to other institutions for research, and if paraffin-embedded sections of surgically excised tumor tissue were available for that patient.
2)The institutions that participated in this study generally require that subject consent be obtained and a record of that consent be created prior to the start of a clinical study before they send a sample to another institution.
However, in the event that it is not possible to obtain said consent because a patient is dead or cannot be contacted, samples may be sent to a central pathology review office if various provisions based on the Ethical Guidelines for Medical and Health Research Involving Human Subjects are met and authorization is obtained from each institutional review board and a representative of each participating institution.
Key exclusion criteria 1) Patients judged by their physician to be unfit to participate in this study
2) Patients who declined to consent to research use of their samples
Target sample size 800

Research contact person
Name of lead principal investigator
1st name Shinji
Middle name
Last name Ohno
Organization The Cancer Institute Hospital of Japanese Foundation for Cancer Research
Division name Breast Oncology Center
Zip code 135-8550
Address 3-8-31, Ariake, Koto-ku, Tokyo, Japan
TEL 03-3520-0111
Email shinji.ohno@jfcr.or.jp

Public contact
Name of contact person
1st name Yoshiyuki
Middle name
Last name Katakura
Organization SRL Medisearch Inc.
Division name Clinical Research Development
Zip code 1631310
Address shinjuku I-Land-Tower 10F, 6-5-1, Nishishinjuku, Shinjuku-ku, Tokyo, Japan
TEL 03-6692-0499
Homepage URL
Email sme.n-sas_cubc@miraca.com

Sponsor
Institute SRL Medisearch Inc.
Institute
Department

Funding Source
Organization TAIHO PHARMACEUTICAL CO., LTD.
Organization
Division
Category of Funding Organization Profit organization
Nationality of Funding Organization

Other related organizations
Co-sponsor
Name of secondary funder(s)

IRB Contact (For public release)
Organization The Cancer Institute Hospital of Japanese Foundation for Cancer Research Ethics Committee
Address 3-8-31, Ariake, Koto-ku, Tokyo, Japan
Tel 03-3570-0210
Email med.shinsa@jfcr.or.jp

Secondary IDs
Secondary IDs NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW

Institutions
Institutions 愛知県がんセンター中央病院(愛知県)、青森県立中央病院(青森県)、旭川医科大学病院(北海道)、岩国医療センター(山口県)、大分県立病院(大分県)、大阪警察病院(大阪府)、大阪国際がんセンター(大阪府)、大阪市立大学医学部附属病院(大阪府)、春日部市立病院(埼玉県)、神奈川県立がんセンター(神奈川県)、亀田総合病院(千葉県)、川崎医科大学附属病院(岡山県)、関西労災病院(兵庫県)、北九州市立医療センター(福岡県)、岐阜市民病院(岐阜県)、岐北厚生病院(岐阜県)、京都大学医学部附属病院(京都府)、近畿大学病院(大阪府)、釧路労災病院(北海道)、呉医療センター中国がんセンター(広島県)、群馬県立がんセンター(群馬県)、群馬大学医学部附属病院(群馬県)、慶應義塾大学病院(東京都)、厚生連高岡病院(富山県)、国立国際医療研究センター病院(千葉県)、九州医療センター(福岡県)、国立病院機構 九州がんセンター(福岡県)、埼玉県立がんセンター(埼玉県)、さいたま赤十字病院(埼玉県)、埼玉メディカルセンター(埼玉県)、静岡県立総合病院(静岡県)、東京女子医科大学東医療センター(東京都)、市立東大阪医療センター(大阪府)、聖隷浜松病院(静岡県)、聖路加国際病院(東京都)、千葉県がんセンター(千葉県)、東北大学病院(宮城県)、徳島大学病院(徳島県)、栃木県立がんセンター(栃木県)、虎の門病院(東京都)、長崎みなとメディカルセンター市民病院(長崎県)、名古屋市立大学病院(愛知県)、名古屋大学医学部附属病院(愛知県)、日本赤十字社医療センター(東京都)、浜松医療センター(静岡県)、県立広島病院(広島県)、福岡大学病院(福岡県)、福島県立医科大学医学部(福島県)、星総合病院(福島県)、国立病院機構 北海道がんセンター(北海道)、松山赤十字病院(愛媛県)、三井記念病院(東京都)、八尾市立病院(大阪府)

Other administrative information
Date of disclosure of the study information
2016 Year 06 Month 01 Day

Related information
URL releasing protocol
Publication of results Unpublished

Result
URL related to results and publications
Number of participants that the trial has enrolled 707
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description

Progress
Recruitment status No longer recruiting
Date of protocol fixation
2016 Year 02 Month 12 Day
Date of IRB
2016 Year 02 Month 12 Day
Anticipated trial start date
2018 Year 05 Month 31 Day
Last follow-up date
2019 Year 01 Month 16 Day
Date of closure to data entry
2019 Year 03 Month 13 Day
Date trial data considered complete
2019 Year 03 Month 14 Day
Date analysis concluded
2019 Year 11 Month 14 Day

Other
Other related information Study design:
cross-sectional method

Subjects:
Subjects were the 1054 patients enrolled and analyzed in the N-SAS-BC 01 and CUBC trials.
In the N-SAS-BC 01 trial, patients were enrolled between October 1996 and April 2001
In the CUBC trial, patients were enrolled between September 1996 and July 2000.

Evaluation items:
ER, PgR, HER2, Ki67, Tumor infiltrating lymphocyte(Tils), Nuclear grading, Histological grading

Management information
Registered date
2016 Year 06 Month 01 Day
Last modified on
2020 Year 06 Month 03 Day


Link to view the page
URL(English) https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000026003

Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name


Contact us.